# Integrated pan-cancer analysis revealed therapeutic targets in the ABC transporter protein family

## TL;DR

This study identifies ABCA10 and ABCB5 as potential therapeutic targets in various cancers by analyzing their expression patterns and impact on survival and immune responses.

## Contribution

The first comprehensive pan-cancer analysis of ABCA10 and ABCB5, revealing their roles in tumor biology and clinical outcomes.

## Key findings

- ABCA10 shows reduced expression while ABCB5 displays variable expression patterns across tumors.
- Expression patterns of ABCA10 and ABCB5 correlate with worse survival outcomes in many cancer patients.
- ABCA10 and ABCB5 are associated with immunotherapy responses and immune infiltration across tumor types.

## Abstract

Next-generation sequencing technology enables uniform and impartial assessment of cancer diagnoses and prognosis. However, such studies are mostly type-specific, and capturing shared genomic abnormalities responsible for neoplastic transformation and progression is a challenging task. Pan-cancer analysis offers insights into the shared and unique molecular mechanisms driving cancer. We conducted an integrated gene-expression analysis using 10,629 samples from 30 distinct cancer types characterized by The Cancer Genome Atlas (TCGA). A gene co-expression network was constructed and genes overlapping between the selected modules and Differentially Expressed Genes (DEGs) were designated as genes of interest. Following a comprehensive literature review, ATP binding cassette subfamily A member 10 (ABCA10) and ATP binding cassette subfamily B member 5 (ABCB5) were selected as key candidates for downstream analysis due to the absence of systematic pan-cancer analysis of these genes. This study presents a unique contribution as the first comprehensive pan-cancer analysis of ABCA10 and ABCB5, highlighting their roles in tumor biology and clinical outcomes. We employed a variety of bioinformatics tools to explore the role of these genes across different tumors. Our research demonstrated that ABCA10 shows reduced expression, while ABCB5 displays variable expression patterns across tumors, indicating their opposing roles and flexible functions in pan-cancer. In many cancer patients, these expression patterns are correlated with worse survival outcomes. Furthermore, immunotherapy responses and immune infiltration across a variety of tumor types are associated with the expression levels of both ABCA10 and ABCB5. These results imply that ABCA10 and ABCB5 could serve as valuable predictive markers and potential therapeutic targets across various cancers.